Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05713760 · ClinicalTrials.gov registry record · Phase 2
Proof of Concept Study to Access Superficial Basal Cell Carcinoma in Adults
A Phase 2 study of Superficial Basal Cell Carcinoma, sponsored by Austin Institute for Clinical Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT05713760: Completed Phase 2 study of Superficial Basal Cell Carcinoma, sponsored by Austin Institute for Clinical Research.
NCT05713760 is a Phase 2 study of Superficial Basal Cell Carcinoma that has completed, run by Austin Institute for Clinical Research. The registered enrollment target is 5 participants, below the 115-participant average among 5 other Superficial Basal Cell Carcinoma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05713760, a Phase 2 study of Superficial Basal Cell Carcinoma, has completed, sponsored by Austin Institute for Clinical Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2, Single-Arm, Open-Label, Single Center, Proof of Concept Study to Assess Efficacy and Safety of Tirbanibulin Ointment 1% in Adult Subjects with superficial basal cell carcinoma (sBCC) on the neck, trunk, or extremities (excluding, axilla, anogenital, and face/scalp).
Primary Outcome
The primary efficacy endpoint will be the percent of subjects with both clinical and pathological clearance of sBCC lesion for subjects who completed 1 course of treatment and subjects who completed 2 courses of treatment.
Conditions Studied
Interventions
- DRUG Tirbanibulin Ointment 1%
Study Locations (1)
Texas
- Austin Institute for Clinical Research, Inc. - Pflugerville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-04-17 |
| Est. Completion | 2024-03-07 |
| Phase | Phase 2 |
What the finished NCT05713760 record still lists
NCT05713760 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 115-participant average among 5 other Superficial Basal Cell Carcinoma trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Superficial Basal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Tirbanibulin Ointment 1% is the first listed.
NCT05713760 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05713760 about?
NCT05713760 is a clinical study titled "Proof of Concept Study to Access Superficial Basal Cell Carcinoma in Adults". This is a Phase 2, Single-Arm, Open-Label, Single Center, Proof of Concept Study to Assess Efficacy and Safety of Tirbanibulin Ointment 1% in Adult Subjects with superficial basal cell carcinoma (sBCC) on the neck, trunk, or extremities (excluding, axilla, anogenital, and face/scalp).
What is the current status of trial NCT05713760?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2023-04-17. Estimated completion is 2024-03-07.
What conditions does trial NCT05713760 study?
This clinical trial studies the following conditions: Superficial Basal Cell Carcinoma.
What interventions are being tested in trial NCT05713760?
The interventions under investigation include: Tirbanibulin Ointment 1% (DRUG).
Who is sponsoring clinical trial NCT05713760?
This trial is sponsored by Austin Institute for Clinical Research, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05713760 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Superficial Basal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer
RECRUITING · Phase 2
-
To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC
COMPLETED · Phase 2
-
A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma
RECRUITING · Phase 1
-
Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma
RECRUITING · NA
-
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI